Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.
Phase:
PHASE2
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)